Intel dives on weak results, guidance

Intel dives on weak results, guidance

Up next

Levi's frayed forecast

Levi beat on revenue and profit. (00:13) Shares fell anyway. Monster sets the date for a 2-for-1 split. (01:33) Burry bets on betting. (02:05)Episode transcripts seekingalpha.com/wsb.Show links: Biggest stock movers Thursday: AZN, AP, and moreSK Hynix US listing said to be over s ...  Show more

STAAR prelims signal upside

STAAR Surgical (STAA) announces preliminary net sales for first quarter 2026. (00:14) Disney (DIS) plans 1,000 job cuts in marketing overhaul under new CEO Josh D’Amaro. (01:15) Cheap semaglutide copies in India challenge Novo Nordisk, cut Eli Lilly’s lead: report. (02:07)Episode ...  Show more

Recommended Episodes

Intel "Stumbles", Inflation Eases, AmEx Rallies and Chevron Posts Record Profit 1/27/23
Squawk on the Street

Carl Quintanilla and Jim Cramer focused on shares of Intel tumbling after the chipmaker posted fourth-quarter results that missed expectations -- and warned of a loss in Q1. The anchors reacted to CEO Pat Gelsinger's earnings call comment: "We realize that we stumbled." The Fed's ...  Show more

Intel in slide: a chipmaker on the ropes
The Intelligence from The Economist

Layoffs, suspended dividends, a share price in free fall, a chief executive hustled out the door: Intel is in <a href="https://www.economist.com/business/2024/12/02/intels-troubles-deepen-as-its-boss-makes-an-abrupt-exit?utm_campaign=a.io&utm_medium=audio.podcast.np&utm_source ...

  Show more

Netflix Shares Drop After Earnings, and the Top Biotech Analyst Dissects the Race for a COVID Cure
CNBC's "Fast Money"

Netflix stock dropped after the company posted disappointing subscriber growth and earnings for the latest quarter. Plus results from Snap and Texas Instruments. And Institutional Investor’s Top-Rated Biotech Analyst breaks down the outlook for companies racing to bring a coro ...

  Show more

Big Tech Reports… And Eli Lilly’s Letdown 10/30/24
CNBC's "Fast Money"

Meta and Microsoft in focus, as the big tech names report results. How our traders are handling the moves, and what it means for entire tech trade. Plus Eli Lilly getting hit, as the pharma stock misses estimates and slashes guidance. So are the disappointing results a sign th ...

  Show more